Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …
Followers of film will be only too aware that we are about to embark on ‘Oscar season’. Cinematic features are …

Bayer has been accused of a “shocking error of judgement” after promotional material for its erectile dysfunction brand Levitra (vardenafil) …
Virgo Health has expanded its medical education and ethical health teams with two new appointments. Danielle James (pictured) has been …
Replacing NICE with a similar system would be detrimental to UK healthcare, according to the Stockholm Network, which further warns …
US pharmaceutical company B.
French pharmaceutical company NicOx is to halve the workforce at its Sophia Antipolis headquarters and is considering restructuring its Italian …

Woolley Pau has promoted senior copywriter Yvette Cumbers and senior art director Eric Houseknecht to the level of deputy creative …
Online healthcare professional network Doctors.net.uk has made three business development appointments and added a new project manager to its team. …
Since spring I have been dealing with a team of builders who have missed every deadline possible, to the extent …
Biogen Idec is set to cut hundreds of jobs and refocus its R&D in an effort to cut costs by …

Pharma companies in the UK have agreed to restrict their promotional giveaways and to declare payments to doctors. Another common …
Faced with a changing healthcare environment and the prospect of diminishing commercial returns, pharmaceutical companies must undertake a fundamental and …

A quarter of comments on the 15 largest Facebook communities for diabetes patients are promotional – generally for non-FDA approved …
Swedish specialty pharmaceutical company Medivir has appointed Charlotte Edenius to the newly created position of VP of research and development …
Drug development studies are extremely expensive, costing many millions of pounds and taking up to 12 years to bring a …

US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …
Neurological disorder specialist Lundbeck has posted a modest growth in revenue for the third quarter, but warned the looming patent …
Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
The integration of Wyeth into Pfizer continues to drive its revenue growth, but at a cost – charges from the …